ArticlePharmaceuticals (Basel, Switzerland)2021

The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2-GATA4 Signaling Pathway.

Kana Shimizu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.